ClinicalTrials.gg
RecruitingNCT07854600Updated Oct 2, 2026

A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer

A Phase 2 interventional study of Ivonescimab and GEMOX Regimen in Biliary Tract Cancer (BTC), sponsored by Haitao Zhao, MD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Haitao Zhao, MD · Phase 2, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Biliary Tract Neoplasms with a site in China — 94 open to participants now, 112 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
61st of 158
87 · median 61
Started
2026
with 33 others
Phase 2
95 of 177
53 open now
Primary completion
2028-10
later than 89 of 111 live
Registered
172nd of 177
by date

Among the 177 studies in Biliary Tract Neoplasms with a site in China, this one is the 61st largest by planned enrollment of the 158 interventional ones that give a count, is one of 34 that started in 2026, is one of 95 in phase 2, reaches primary completion later than 89 of the 111 other live ones, and was the 172nd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

94 of the 177 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to explore the efficacy and safety of Ivonescimab in combination with GEMOX chemotherapy as neoadjuvant and conversion therapy for patients with biliary tract cancer. It aims to evaluate the impact of this combination regimen on postoperative recurrence, patient survival, and medication safety.

This is a single-center, phase II, interventional, single-arm, multi-cohort clinical study. A total of 87 eligible participants will be enrolled and assigned to either the neoadjuvant therapy cohort (45 participants) or the conversion therapy cohort (42 participants).

03

Conditions studied

  • Biliary Tract Cancer (BTC)

Keywords

  • Ivonescimab
  • Neoadjuvant Therapy
  • Conversion Therapy
  • Biliary Tract Cancer
  • GEMOX Regimen
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subjects voluntarily participate in the study, agree to sign a written form, demonstrate good compliance, and are willing to cooperate with follow-up.
  • 2. Male or female aged >= 18 and \<= 80 years at the time of signing the ICF.
  • 3. or cytologically confirmed biliary tract cancer (BTC, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer), and radiologically assessed as locally advanced or with oligometastases (defined as Stage IIIA or higher lesions according to the 8th edition of the AJCC staging system). Subjects must agree to provide archived or fresh tumor specimens and peripheral blood samples for biomarker testing.
  • 4. Lesion assessment meets one of the following conditions:
  • Therapy Cohort: The tumor is graded as locally advanced with no distant , and theoretically can achieve radical resection through complex resection combined with vascular reconstruction, but both the surgical risk and postoperative recurrence risk are high (single tumor diameter > 5 cm; imaging suggests vascular invasion or hilar lymph node metastasis; tumor number > 3 or any single tumor > 3 cm; preoperative CA19-9 > 37 U/mL or exceeding the [applicable to centers where the normal range is not \< 37 U/mL]).
  • Conversion Therapy Cohort: The tumor is graded as locally advanced, unresectable, or combined with oligometastatic status (oligometastasis is defined as: metastatic lesions confined to a single organ or specific regional lymph nodes, and the number of metastatic lesions is \<= 5), with the possibility of achieving radical resection of the primary lesion and no evidence of disease (NED) status for metastatic lesions after comprehensive treatment.
  • 5. At least one (according to v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan >= 10 mm or the shortest diameter of enlarged lymph nodes >= 15 mm).
  • 6. No prior systemic therapy for biliary tract cancer.
  • 7. (ECOG) performance status score of 0 to 1.
  • 8. class A liver function.
  • 9. Normal bone marrow, liver, and kidney function, meeting the following clinical laboratory evaluation criteria within 7 days prior to treatment (the conditions cannot be met by administering any blood components, cell growth factors, albumin, or other corrective medications within 14 days prior to obtaining the laboratory tests; patients developing obstructive jaundice after percutaneous transhepatic cholangial drainage [PTCD] or endoscopic retrograde cholangiopancreatography [ERCP] treatment may be considered for enrollment if liver function indicators meet the inclusion criteria):

    1. (ANC) >= 1.5 x 10\^9/L, count >= 90 x 10\^9/L, >= 90 g/L; and ALT \<= 3 x ULN (upper limit of normal); TBil \<= 1.5 x ULN;
    2. Hemoglobin > 9 g/dL without blood transfusion or use of erythropoietin within the past 14 days;
    3. Serum creatinine \<= 1.5 x ULN and rate (calculated using Cockcroft-Gault formula) >= 60 ml/min;
    4. Good coagulation function, (INR) \<= 1.2 or Prothrombin Time (PT) \<= 1.2 x ULN;
    5. Normal thyroid function, defined as Thyroid Stimulating Hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range are also eligible;
    6. Myocardial enzyme spectrum within the normal range (isolated laboratory abnormalities judged by the investigator to have no clinical significance are also permitted).
  • 10. Subjects with previous or current Virus (HBV) or Virus (HCV) infection must have received standard antiviral therapy, and the investigator must confirm that the current liver disease status is stable and suitable for receiving the study treatment.
  • 11. Women of : agree to use effective methods during the study period and for 120 days after the last dose, and have a negative urine or serum pregnancy test within 7 days prior to the first dose.
  • 12. Men: agree to use effective contraceptive methods during the study period and for 120 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • 1. Diagnosed with mixed periampullary cancer, or mixed hepatocellular-cholangiocarcinoma.
  • 2. Prior systemic anti-tumor therapy for BTC.
  • 3. Prior treatment with gemcitabine-based chemotherapy, platinum-based chemotherapy, or any tumor immunotherapy/targeted therapy (e.g., /PD-L1 inhibitors, VEGF inhibitors, etc.).
  • 4. History of severe allergy to other monoclonal antibodies. Known severe allergy or intolerance to gemcitabine, platinum drugs, or any of their components/.
  • 5. Known allergy or intolerance to recombinant humanized PD-1 monoclonal antibody drugs, VEGF monoclonal antibody drugs, and their components (or any excipients), or a history of severe allergy to other monoclonal antibodies.
  • 6. Pericardial effusion, uncontrollable pleural effusion, or ascites within 7 days prior to treatment, defined as meeting the following criteria: (a) ascites detectable by physical examination during the screening period, or (b) ascites requiring therapeutic paracentesis during the screening period.
  • 7. Clinical evidence of portal hypertension with esophageal or gastric varices within 6 months prior to the start of treatment.
  • 8. Any bleeding or thrombotic disorders within 6 months prior to the start of treatment, or currently taking any anticoagulants (e.g., warfarin or similar drugs) requiring monitoring of the (INR) during treatment.
  • 9. History of any malignant tumor, except for the BTC studied in this clinical trial and cured locally recurrent cancers (e.g., resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical cancer or breast cancer in situ, occult thyroid cancer).
  • 10. Known central nervous system and/or prior to treatment.
  • 11. History of any active immunodeficiency or disease, and/or any immunodeficiency or autoimmune disease that may relapse at the time of screening.
  • 12. Any severe chronic or active infection (except viral hepatitis) requiring systemic antibacterial, antifungal, or antiviral therapy (e.g., tuberculosis) prior to the start of treatment.
  • 13. (ECG) during screening shows a heart rate- interval (QTc) (corrected using Fridericia's formula) exceeding 450 milliseconds. Note: If the QTc interval exceeds 450 milliseconds on the first ECG, a repeat ECG will be performed to confirm the result.
  • 14. Presence of any of the following cardiovascular risk factors: cardiogenic chest pain within 28 days prior to treatment, defined as moderate pain limiting activities of daily living (ADL); symptomatic pulmonary embolism within 28 days prior to treatment; acute myocardial infarction within 6 months prior to treatment; history of (NYHA) Class III or IV heart failure within 6 months prior to treatment; Grade >= 2 ventricular arrhythmia within 6 months prior to treatment; cerebrovascular accident (CVA) or (TIA) within 6 months prior to treatment.
  • 15. Organ transplantation or hematopoietic stem cell transplantation () or any major surgery within 28 days prior to treatment.
  • 16. Known psychiatric or substance abuse disorders that may interfere with cooperation in the trial.
  • 17. Receipt of within 28 days prior to treatment. Note: Seasonal influenza vaccines are generally inactivated influenza vaccines and are permitted.
  • 18. Known history of (HIV) infection or syphilis infection.
  • 19. Any history of disease, treatment, or laboratory abnormalities that, in the opinion of the principal investigator, may confound the test results, interfere with the subject's participation throughout the trial, or are not in the best interest of the subject.
  • 20. Currently participating in and receiving treatment in another drug or device study, or having participated in such studies within 4 weeks prior to the first dose of the study drug.
  • 21. Pregnant or breastfeeding from the screening visit to 120 days after the last dose, or expecting to conceive or give birth within the planned duration of the trial.
  • 22. Poor compliance as judged by the investigator, or presence of other conditions making the patient unsuitable to participate in this trial.
  • 23. Presence of multiple medical making it unsuitable to undergo contrast-enhanced imaging (CT or MRI) examinations.
  • 24. Presence of surgical contraindications; patients deemed unsuitable for surgery by the investigators.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    Ivonescimab + GEMOX

    Participants in both the neoadjuvant therapy cohort and the conversion therapy cohort belong to this single experimental arm. All participants will receive 3 to 6 cycles of Ivonescimab in combination with GEMOX chemotherapy prior to surgical evaluation.

    Drug: Ivonescimab · Drug: GEMOX Regimen

Interventions

  • Administered at a dose of 20 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) in combination with GEMOX chemotherapy for 3 to 6 cycles. For eligible patients in the conversion therapy cohort who do not undergo surgery after evaluation, Ivonescimab is continued as maintenance monotherapy (20 mg/kg, IV, Q3W, Day 1) until disease progression, unacceptable toxicity, death, withdrawal of consent, or investigator decision.

    Also known as: AK112

  • DrugGemcitabine-oxaliplatin regimenStudies of Gemcitabine-oxaliplatin regimenGemcitabine-oxaliplatin regimen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The GEMOX regimen consists of Gemcitabine (1000 mg/m²) and Oxaliplatin (100 mg/m²). Both drugs are administered via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). This chemotherapy regimen is administered in combination with Ivonescimab for 3 to 6 cycles prior to surgical evaluation.

    Also known as: Gemcitabine and Oxaliplatin

06

What researchers measure

Primary outcomes

  1. R0 Resection Rate

    The proportion of participants in the neoadjuvant therapy cohort who undergo surgical resection and achieve microscopically margin-negative (R0) resection.

    Time frame: Up to 6 weeks post-surgery

  2. Objective Response Rate

    The proportion of participants in the conversion therapy cohort achieving a Complete Response (CR) or Partial Response (PR) based on RECIST v1.1 criteria as assessed by investigators.

    Time frame: Up to 24 weeks (assessed after 3-6 cycles of treatment)

Secondary outcomes

  1. Objective Response Rate

    The proportion of participants in the neoadjuvant cohort achieving CR or PR based on RECIST v1.1.

    Time frame: Up to 10 weeks from baseline (assessed pre-operatively)

  2. R0 Resection Rate

    The proportion of participants in the conversion cohort who achieve resectability and obtain an R0 resection post-surgery.

    Time frame: Up to 4 weeks post-surgery (assessed upon availability of postoperative pathology report)

  3. Pathological Response Rate

    The proportion of participants who achieve Major Pathological Response (MPR) or Pathological Complete Response (pCR) confirmed by postoperative pathology.

    Time frame: Up to 4 weeks post-surgery

  4. Disease Control Rate

    The proportion of participants achieving CR, PR, or Stable Disease (SD) based on RECIST v1.1.

    Time frame: Up to 19 weeks from baseline (assessed pre-operatively)

  5. Incidence and Severity of Adverse Events

    Incidence of AEs, Serious Adverse Events (SAEs), drug-related AEs, and specific AEs assessed per NCI CTCAE v5.0. This includes continuous monitoring of vital signs and laboratory parameters.

    Time frame: Up to 28 days after the last dose of study treatment

  6. Event-Free Survival

    The time from study enrollment to the first occurrence of disease progression precluding surgery, local/regional recurrence after surgery, distant metastasis, or death from any cause.

    Time frame: Up to 24 months

  7. Progression-Free Survival

    The time from study enrollment of the conversion therapy cohort to the first documented objective tumor progression per RECIST v1.1 or death from any cause.

    Time frame: Up to 24 months

  8. Relapse-Free Survival

    The time from surgical resection to the first occurrence of disease recurrence (local, regional, or distant) or death from any cause among patients who underwent surgery.

    Time frame: Up to 24 months

  9. Overall Survival

    The time from study enrollment to death from any cause.

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100730, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 2, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854600
Lead sponsor
Haitao Zhao, MD
Responsible party
Haitao Zhao, MD (Deputy Director, Department of Hepatic Surgery, Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Haitao Zhao, DR
Contact
zhaoht@pumch.cn
+86-10-69156042

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivonescimab · Gemcitabine-oxaliplatin regimen

Start the discussion